Founder and Chief Executive Officer; formerly CEO, PureTech Health, Seaport Therapeutics
Search every verified Daphne Zohar interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Daphne Zohar, founder and CEO of PureTech Health, discussed the company's evolution and approach to biotech entrepreneurship in a May 2021 podcast appearance. She described PureTech's origins in 2005 as a venture creation model that tested academic concepts and launched subsidiary companies, including Vidanta Biosciences and Achily Interactive. According to Zohar, PureTech has since transitioned toward a more traditional R&D biotech model focused on the "brain-immune-gut axis," particularly treatments intervening in the lymphatic system, and is now advancing therapies further in clinical development on its own. She noted that 24 therapeutic candidates have emerged from the company's engine, with two receiving FDA approval. Zohar also reflected on her approach to navigating biotech development, emphasizing the need to balance "really exciting breakthrough science" with what is actionable within near-term budget constraints. She said PureTech's model includes running experiments designed to "kill the project," whether through key pre-clinical work replicating academic findings or other tests. In a personal aside, she connected the company's naming of Karuna to the concept of relieving suffering, one of the four sublime states, and expressed hope in moments of humanity amid divisiveness.
Panel: Rare & Neuro Diseases Panelists: Daphne Zohar, Founder & Chief Executive Officer, Seaport Therapeutics Dr. Fiona Elwood, Vice President, Neurodegeneration DAS, J&J Innovative Medicine Dr. Priya Singhal, Executive Vice President & Head of Development, Biogen Dr. Nancy Andrews, Executive Vice President & CSO, Boston Children’s Hospital Dr. Zandy Forbes, President & CEO, MeiraGTx Moderator: Dr. Steve Uden, Co-Founder & CEO, Rallybio
Daphne Zohar, CEO of Puretech Health, on starting biotech companies.
In this episode of Second Opinion, hosts Christina Farr, Ash Zenooz, and Luba Greenwood are joined by Daphne Zohar, Founder and CEO of Seaport Therapeutics. They talk about the complexities of drug development, the investment in biotech via big tech VCs, and the future of mental health treatments. Daphne also shares her insights on biotech today, drug development misconceptions and complex regulatory challenges the industry is facing. Daphne was the founder, CEO and a Board Member of PureTech Health (Nasdaq: PRTC, LSE: PRTC) where she also co-founded PureTech’s entities, including Karuna Thera…
In Episode 12, Season 4 of the Amplifying Scientific Innovation® Video Podcast, Dr. Sophia Ononye-Onyia, Founder and CEO of The Sophia Consulting Firm, interviewed Ms. Daphne Zohar, Founder and CEO of Boston-based PureTech Health, a clinical-stage biotherapeutics company that she founded over 17 years in the U.S's largest biotech cluster with the goal of developing BIG (Brain-Immune-Gut) Medicines. Here, Ms. Zohar discusses her unique perspectives on science advocacy, health equity and influential leadership. For full transcript, please visit: https://sophiaconsultingfirm.com/blog...
Daphne Zohar, CEO of PureTech, traced her entrepreneurial journey from high school to biotech CEO, in an engaging and informative talk with my students.
In this episode of our Health Innovators series, Paul Tunnah interviews Daphne Zohar, the co-founder and CEO of PureTech Health, a public biotech listed on the London Stock Exchange. Lydia discusses PureTech’s pipeline projects which are focused on the BIG (Brain-Immune-Gut) axis and the company’s interest in digital therapeutics.
Daphne Zohar is the Founder and Chief Executive Officer of PureTech Health (PRTC.L) and a member of the Board of Directors. Here, we talk about PureTech's origins, its pivot, and how its model is designed to be different. PureTech Health is an advanced, clinical-stage biopharmaceutical company developing novel medicines targeting serious diseases that result from dysfunctions in the nervous, immune, and gastrointestinal systems (brain-immune-gut or the “BIG” axis), which together represent the adaptive human systems. PureTech Health is at the forefront of understanding and addressing the bio…
NewYorkBIO's breakfast series has gone virtual! Providing engaging speakers on innovation, clinical development, patient engagement and more cutting topics across the biopharmaceutical industry. These events are held live every Tuesday morning at 9AM with open registration for all interested participants. Learn more about our organization at www.newyorkbio.org and follow us on Twitter @NewYorkBIO
In this fireside chat brought to you by Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG talks to Daphne Zohar, Founder and CEO of PureTech. Daphne sheds light on how their unique and innovative business model looks to solve unmet needs and problem areas across the industry, how they differ from your typical biotech and the benefit of their problem centric approach. She explores how they’re constantly innovating their internal pipeline and adapting to the needs of the market, such as using LYT-100, an existing program, to treat post-recovery complications from C…
Sign in to search the full transcript archive, filter by topic, and access every quote from Daphne Zohar.
The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →
Pro unlocks every transcript in full, plus unlimited search across every executive and company we cover.
50% off appliedPulling data at scale? The Data API gives you 30,000 transcripts a month over REST, MCP and JSON.
Compare all plans